Excited to share our recent @LancetOncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases. @MDAndersonNews @myriadgenetics https://t.co/UgstAFfvMi

11/ Many thanks to the outstanding study team/coordinators, collaborators & the pts and families who participated in the trial. My special gratitude for the mentorship of @ChadTangMD in this study. Full text: https://t.co/Lm3f4CaQwU

10/ Nonetheless EXTEND is a critical step forward for improving outcomes in oligomet prostate ca and supports the role of MDT with multiple ADT strategies.

9/ EXTEND has important limitations, incl heterogeneity & signal-finding design. Translational findings merit validation in animal models & subsequent trials.

8/ We lastly profiled these immune responses, linking their engagement to prostate ca antigens, leading to the hypothesis that MDT-driven immune education mediates long-term disease control for select pts in this population

7/ For pts with robust immune response to MDT, median PFS was 60 mo, highlighting the underlying a potential means for potentiating long-term control with an MDT-based approach.

6/ We further replicated these findings using samples from the independent ORIOLE trial

5/ How might MDT provide systemic disease control? We explored immune responses to MDT and found multiple measures of immune activation linked to clinical outcomes including TCR clonal expansion.

4/ MDT+cADT met the primary endpoint, with median PFS of 47 mo vs 22 with cADT alone.

3/ Thus EXTEND had 2 baskets for oligomet prostate ca, one for each commonly used ADT backbone. Each basket was independently randomized, stratified & powered

2/ Previously we reported a separate basket of EXTEND evaluating intermittent ADT +/- MDT, with MDT meeting the PFS primary endpoint. Intermittent ADT is appealing for select pts, though continuous ADT is SOC for met prostate ca. https://t.co/hMBVzj4vkp

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others

1/5 How reproducible are phase III oncology trials? 📊 With @AlexSherryMD @ErikVanZwet @ebludmir et al. We analyzed 632 RCTs (~496,000 pts). The data offer both reassurance and caution for clinicians and researchers. https://t.co/SgrRgv38UI 👇#MsaouelLab

Just 2 incoming @MayoRadOnc faculty enjoying the views & company at the @JAMAOnc reception. #ASCO25

👥Case-Based Session: Evolving Landscape of the Management of Oligometastatic Disease #GU25 🐺Dr @ChadTangMD presenting Abs15 "World-wide oligometastatic prostate cancer (omPC)meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): An analysis

Does SBRT for oligorecurrent #prostatecancer improve overall survival as compared to SOC? WOLVERINE reporting on STOMP, ORIOLE, EXTEND and ARTO. Presented by @ChadTangMD at #GU25.

Proud to present the results of the EXTEND breast basket led by #JayReddy from @MDAndersonNews in the @IJROBP . This is a randomized trial of oligometastatic breast cancer patients randomized to +/- MDT. Unfortunately not all trials were positive. https://t.co/7D5ZIwfOFE

Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology: https://t.co/6XdSbIhvUu @AlexSherryMD @ebludmir @PavlosMsaouel @ErikVanZwet

Most grateful for the terrific collaboration with @ErikVanZwet and mentorship of @PavlosMsaouel @ebludmir on this exciting methodology work. @MDAndersonNews #radonc #bayesian #Oncology

We provide the underlying code as well as a very user-friendly shinyapp for anyone to calculate posteriors and probabilities at any effect level of interest: https://t.co/98LKTDIn3n